

(Research Article)



Received on 09/01/2012;


Revised on 25/01/2012;

Accepted on 13/02/2012.

“RP-HPLC Method Development and Validation of Lamotrigine in Tablet Dosage Form”

Ankit Patel*, Mahesh Kumar Kataria.

Seth G. L. Bihani S. D. College Of Technical Education¹, Sri Ganganagar, Rajasthan,



Corresponding Author:

Ankit Patel*¹

Seth G. L. Bihani S. D. College Of Technical Education¹, Sri Ganganagar, Rajasthan, (India)

E mail: ankit_patel44439@yahoo.in

ABSTRACT

A simple, rapid and precise method was developed for the quantitative determination of Lamotrigine in tablet dosage form. The method was based on RP-HPLC. Chromatographic separation was performed on a fortis C18 (150mm X 4.6mm and equivalent 5 μ m) column using a mobile phase of acetonitrile (ACN) and phosphate buffer (0.05mol) ratio 20:80 at pH 2.5 adjusted with dilute orthophosphoric acid. The following system conditions were maintained throughout development and validation i.e., flow rate of mobile phase 1ml/min, column temperature at 40°C and the detecting of drug by a UV-wave length at 270 nm. The Lamotrigine was well resolved on the stationary phase and the retention time was 5.1 minute. The method was validated the drug was shown to be linear for drug in 10-30 μ g /ml. the correlation coefficient (r^2) for the drug was 0.998. The Precision, Accuracy, LOD and LOQ were determined to validate the method.

KEY WORDS: Lamotrigine, RP-HPLC, Method development, Validation and C18 Column.

(Research Article)**INTRODUCTION**

Lamotrigine [6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine] is a broad spectrum antiepileptic drug, chemically different from other anti-convulsants. The mechanism of action of Lamotrigine is inhibition of the release of excitatory neurotransmitters (aspartate and glutamate) and also involvement of the blocking of voltage dependent sodium channels^{1,3}. Lamotrigine is effective for treatment of partial and generalized tonic, chronic seizures as a single drug or as an adjuvant with other anti epileptic drugs⁴.

INSTRUMENT

The liquid chromatographic system used was an isocratic HPLC Shimadzu system consisting of pump (LC-10ATVP, Shimadzu, Japan), UV-Vis detector (SPD-10A Shimadzu) equipped with LC solution 2010 software and a sample injector fitted with a 20 μ l sample loop. The chromatographic separation was carried out on Fortis C18 (150cm X 4.6mm and equivalent 5 μ m) column. The mobile phase was 0.05M Potassium dihydrogen ortho phosphate: ACN (80:20 v/v) adjusted to pH 2.5 with dilute ortho phosphoric acid and filtered with whatman filter paper. All the separations were performed isocratically at a flow rate of 1ml /min at room temperature. The peak area was determined using a UV detector at a wave length of 270nm.

MATERIALS AND METHODS

Lamotrigine as the reference standard was provided from Torrent Pharma. The chemicals of analytical reagent grade purchased from various sources. All solvents for analysis including water

for HPLC grade obtained from fisher Quallizene and Merck.

Experiment**Preparation of solutions****Buffer Preparation**

1.36g of potassium dihydrogen Orthophosphate was dissolved in 1000ml water 1 ml triethylamine (TEA) and pH 2.5 was adjusted with orthophosphoric acid and mixed well.

Diluent preparation

Water: Methanol in the ratio of (40:60) v/v was used.

Standard Preparation (20ppm)

Accurately 40.0 mg of Lamotrigine was weighed & transferred into volumetric flask of 100ml. About 60 ml of methanol was added and sonicated to dissolve. The volume was made up to the mark with methanol and mixed. 5 ml of this solution was diluted to 100ml with diluent (water: methanol 40:60) and mixed.

Sample Preparation (20ppm)

10 tablets were weighted accurately and transfer into volumetric flask 500ml, about 250ml of Methanol was added and sonication was performed for 40minutes with vigorous shaking. After the complete dissolution of tablets, the solution was brought to room temperature and the volume was made up with methanol. 5 ml of this solution was diluted to 250 ml with diluent and mixed. Filter the above solution through 0.45 μ filter.

(Research Article)**Selection of detection wavelength**

Lamotrigine showed the absorbance at 270nm. So the wavelength selected for the determination

of Lamotrigine was 270nm as shown in figure no. 1.




Figure No. 1: UV spectra of Lamotrigine Preparation of Standard Curve:

Preparation of Standard Curve

Linearity was determined at eleven levels over the range of 10 ppm to 30 ppm. A standard stock solution was prepared and further diluted to attain concentrations of 10ppm, 15 ppm, 20 ppm, 25 ppm and 30 ppm and each preparation was injected in duplicates. The mean area at each level was calculated and a graph of mean area

versus concentration in mcg/ml was plotted as shown in Table no. 1 & figure no.2. The correlation co-efficient, y-intercept, slope of regression line and residual sum of squares were calculated and recorded.

Table No. 1 Preparation of Linearity solution for ABC

S. No.	Linearity Level (W.r.t)	Actual Conc. in ppm	Mean Peak Area
1	50%	10	681480
2	75%	15	1016084
3	100%	20	1271759
4	125%	25	1626457
5	150%	30	1934250




Figure No 2: Linearity curve of Lamotrigine

(Research Article)**PROCEDURE**

Blank preparation was injected in RP-HPLC. Standard preparation was run and chromatograms were recorded. The chromatograms were checked for compliance of system suitability test and necessary changes

were made to meet the system suitability requirements. Several trails were taken following this procedure and the results are shown as in table no. 2 and figure no. 3.

Table No 2: Observation for method development for lamotrigine.

Sr. No.	Trials	Observation	Remarks
1	Buffer : MeOH (85:15 % v/v) Flow rate 1.0 ml/min Column:- Fortis C18, 150mm x 4.6mm; 5 μ Buffer:- pH 2.5 KH ₂ PO ₄ Buffer	Tailing, High Retention time	Not Satisfactory
2	Buffer : MeOH (85:15 % v/v) Flow rate 1.0 ml/min Column:- Fortis C18 150mm x 4.6mm; 5 μ Buffer:- pH 2.5 KH ₂ PO ₄ Buffer	Retention time satisfactory but low theoretical plate	Not Satisfactory
3	Buffer : ACN (90:10%v/v) Flow rate 1.0 ml/min Column:- Fortis C18 150mm x 4.6mm; 5 μ Buffer: - pH 2.5 KH ₂ PO ₄ Buffer	High Retention time.	Not Satisfactory
4	Buffer : ACN(85:15%v/v) Flow rate 1.00 ml/min Column:- :-Forts C18 150mm x 4.6mm; 5 μ Buffer: - pH 2.5 KH ₂ PO ₄ Buffer	High Retention time.	Not Satisfactory
5	Buffer: CAN (80:20 %v/v) Flow rate 1.2 ml/min Column:- :-Fortis C18 150mm x 4.6mm; 5 μ Buffer: - pH 2.5 NaH ₂ PO ₄ Buffer	Peak Shape was good , Retention time 5.10 min.	Satisfactory

(Research Article)**FINAL TRIAL**

Column : Fortis, (150mm x 4.6mm), 5 μ m or equivalent
 Flow rate : 1.0 mL/minute
 Detector : UV
 Detector wavelength : 270 nm
 Injection volume: 20 μ L
 Run time : 10 minute
 Diluent : Water: Methanol (40:60) v/v
 Mobile phase : Buffer: Acetonitrile: (80:20) v/v




Figure No 3: Chromatogram of Lamotrigine Standard

RESULTS AND DISCUSSION**Method optimization results****Selection of proper column**

Fortis, (150cm x 4.6mm), 5 μ m or equivalent

Selection of chromatographic conditions

Optimized chromatographic conditions for estimation of Lamotrigine finalized as shown in Table No.2.

Table No 2: Optimized chromatographic conditions

Column	Fortis,(150 x 4.6mm),5 μ m or equivalent
Flow rate	1.0 mL/minute
Detector	UV
Detector wavelength	270 nm

(Research Article)

Injection volume	20 μ L
Run time	10 minute
Diluent	Water: Methanol (40:60) v/v
Mobile phase	Buffer : ACN: (80:20) v/v

The trails with Buffer: Methanol shows hat the peak for lamotrigine drug was resolved in a single HPLC trial run. In gradient start with gradient of Buffer: Methanol it was observed that the tailing & peak produced were not too good, thus the mobile phase was changed. In gradient use ACN at this time peak was satisfactory but retention time was around 9 min. As the ACN was increased in

gradient system, good & sharp peak at 5.10 min. were obtained. The assay of lamotrigine tablet was done by this method and 99.17% result was obtained. The optimized chromatographic conditions and validation parameters are given below in table no. 3.

Table No 3: Result of different parameter

Parameter		Drug
Specificity		Specific
Linearity	Regression equation $y=mx+c$	$y = 62318x+59641$
	Slope	62318
	Intercept	59641
	Correlation coefficient (r^2)	0.998
Accuracy (Recovery) n=6	Level 1	99.9
	Level 2	100.3
	Level 3	98.2
Precision Method precision (Repeatability)		99.3
Intermediate Precision (Ruggedness)		99.4
Robustness (% RSD), n=3		< 2
System Suitability		1.1%

Accurately spiked known quantity of sample in the placebo and the actual quantity recovered were determined to measures the accuracy of the

method. In similar manner the placebo was injected and compared with standard to determine the specificity interference with standard drug.

(Research Article)

There was no interference occurred. This measured the ability of the method to access the analyte specifically in the presence of excipients and other degradants.

In precision the system precision and method precision were determined. The system precision there was repetition of injection with similar batch tablet and observation of the response. The method precision there was repetition of injection from the different batch tablet and observation of the response. In this manner the method precision and system precision was performed. In the study linearity and range were also observed, in which the linear relation between the concentration and the result were found satisfactory.

CONCLUSION

Based on the results, obtained from the analysis of forced degraded samples using described method, it can be concluded that there was no other co-eluting peaks of interference from excipients and degradation products due to

References

- 1 Goa KL, Ross SR, Chrisp P, *Drugs*. 1993, 46, 152-176.
- 2 Brodie MJ, *Lancet*. 1992, 339, 1397-1400.
- 3 Messenheimer JA, *Epilepsia*, 1995, 36 (2), 87-94.
- 4 A W C Yuen, *Epilepsia*, 1994, 35(5), 33-36.
- 5 Morris RG, Black AB, Harris AL, Batty A B, Sallustio BC, *Br. J. Clin. Pharmacol* 1998, 46, 547-551
- 6 Rockville MD, The "United states Pharmacopoeia". XXIV, National Formulary, XIX, US
- 7 Pharmacopoeial Convention, Inc, 2000, 1923.
- 8 Ahuja S, Rasmussen H. HPLC Method Development for Pharmaceuticals, Elsevier Inc, 8(1), 13-15.
- 9 Ayres AH, Quantitative Chemical Analysis, Harper & Row Publishers, 2nd ed. 1999, 165-170.
- 10 Backett AH, Stanlake JB. Practical pharmaceutical chemistry-II. CBS publisher and distributors, Delhi; 4th ed. 2001. Page no. 255-280.

variable stress components with the main peaks. The method is specific for the estimation of Lamotrigine in presence of degradation products. The proposed method shows good agreement with all validation parameters. The optimized method is precise, accurate and robust and so it can be applied as stability indicating for the estimation of Lamotrigine in tablet dosage form. The developed method can be used for the analysis of routine quality control test. In the present work the RP-HPLC method for the estimation of Lamotrigine in solid dosage form has been developed. The proposed method is simple, precise and accurate and do not suffer from any interferences due to common excipients. The newly developed methods can be used in pharmaceutical industry for routine quantitative estimation of Lamotrigine 20mg, 50mg, 100mg, 250mg in tablet dosage form. The developed method was validated as per ICH guidelines and can be used for the analysis of routine quality control sample.

(Research Article)

- 11 Chan c, lam h, lee y, Zhang x, Analytical Method Validation and Instrument Performance Verification, John Wiley & Sons, Inc, Publication, 2004, 16-21.
- 12 Christian GD. Analytical chemistry. John Wiley and Sons, Inc, 1994, 537-540.
- 13 Higuchi T, Einar B, Hanffen H, Hamffen H. Pharmaceutical analysis, 1997, 1-9.
- 14 ICH harmonised tripartite guideline. Validation of analytical procedures: Text and Methodology, ICH Q2 (R1), 2005.
- 15 Jeffery GH, Bassett J, Mendham J, Denney RC, Textbook Of Quantitative chemical Analysis, Longman Singapore Publisher, 1997, 216-17.
- 16 Kazakevich Y, Lobrutto R, HPLC for pharmaceutical scientists, John Wiley & Sons, Inc, 2007, 11-13.
- 17 Quality assurance of pharmaceuticals - A compendium of guidelines and related materials. WHO, Geneva; Volume I, 1997, 119-124.
- 18 Sandie L. HPLC by open learning. John Wiley and Sons, London, 1992, 1-12.
- 19 Sean R, et al. Determination of Lamotrigine in biologic materials by a simple and rapid liquid chromatographic method. Therapeutic drug monitoring, april 1998, 20(2), 209-214
- 20 Sethi PD. Quantitative analysis of drugs in pharmaceutical formulations, CBS publisher and distributors, New Delhi, 1997, 1-2.
- 21 Skoog DA, West DM, Holler JF. Fundamentals of analytical chemistry. Harcourt college publishers, 2001, 701-707.
- 22 Snyder LR. Practical HPLC method development. John Wiley and Sons, London, 1997, 1-10.
- 23 Swarbrick J, Boylan JC. Encyclopedia of pharmaceutical technology. Marcel Dekker Inc, 2002, 1, 363-416.
- 24 US FDA. Technical Review Guide: Validation of Chromatographic Methods, 1993.
- 25 Youssef N, taha E, et al. Development and validation of spectrophotometric, tlc and hplc methods for the determination of Lamotrigine in presence of its impurity, chem. Pharm. Bull. 2007, 55, 541.